New biomarker could predict immunotherapy benefit in breast cancer
The Major Histocompatibility Complex Class II protein has potential to predict immunotherapy benefit in two types of breast cancer.
Risk of delivery complications higher in women with previous or current cancer diagnoses
Pregnant women who had cancer previously or currently have cancer were more likely to experience comorbidities and in-hospital complications, depending on cancer type.
2 Clarke Drive Cranbury, NJ 08512